Patent application number | Description | Published |
20090036435 | Pharmaceutical Compounds - The invention provides a combination of an ancillary agent and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein the ancillary agent is selected from: a monoclonal antibody, an alkylating agent, an anticancer agent, a further CDK inhibitor and a hormone, hormone agonist, hormone antagonist or hormone modulating agent; X is a group R | 02-05-2009 |
20090082370 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents - The invention provides a combination for use as a protein kinase B inhibitor, the combination comprising (or consisting essentially of) an ancillary compound and: (I) a compound of the formula: or salts, solvates, tautomers or N-oxides thereof, wherein R | 03-26-2009 |
20090263398 | PHARMACEUTICAL COMBINATIONS - The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R | 10-22-2009 |
20090298818 | PHARMACEUTICAL COMPOUNDS - The invention provides the use of a compound for the manufacture of a medicament for the treatment of pain, wherein the compound is a compound of the formula (VI): | 12-03-2009 |
20100021420 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S - A combination comprising (a) a compound of formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is R | 01-28-2010 |
20100055094 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA - The invention provides combinations of an ancillary compound and a compound which is a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. Also provided are crystalline forms of the salts, methods for making the salts and their uses in treating cancers. The invention further provides combinations of an ancillary compound and a compound of the formula (I) as defined in PCT/GB2004/002824 (WO 2005/002552) or a compound of the formula (I′) | 03-04-2010 |
20100092474 | PHARMACEUTICAL COMBINATIONS - The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): | 04-15-2010 |
20100152184 | PHARMACEUTICAL COMPOUNDS - The invention provides a compound for use in medicine, the compound being a compound of the formula (VI | 06-17-2010 |
20100166699 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS - The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R | 07-01-2010 |
20100179145 | PHARMACEUTICAL COMBINATIONS - The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): | 07-15-2010 |
20110002879 | Combinations of Pyrazole Kinase Inhibitors - The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib): | 01-06-2011 |
20110046155 | HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 - The invention provides an acid addition salt of a compound of the formula (1) Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogues thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analogue. | 02-24-2011 |
20110105501 | PHARMACEUTICAL COMBINATIONS - The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): | 05-05-2011 |
20110159111 | PHARMACEUTICAL COMBINATIONS - The invention provides combinations of an ancillary compound of the formula (0): and a compound of the formula (I′): Also provided are crystalline forms of the constituent compounds, methods for making them and their uses in treating cancers. | 06-30-2011 |
20140221394 | HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 - The invention provides an acid addition salt of a compound of the formula ( | 08-07-2014 |
20140288040 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION - The invention provides compounds of the formula (6): | 09-25-2014 |
20150051199 | PHARMACEUTICAL COMPOUNDS - The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): | 02-19-2015 |